Registered Nurse in Naugatuck, CT Accepting Medicare

6 Registered Nurse nurses found. Showing 1 - 6

Lorrie Belmonte, RN Registered Nurse - Infection Control Medicare: Not Enrolled in Medicare Practice Location: 89 Weid Dr, Naugatuck, CT 06770 Phone: 203-729-9889

Blerina Petitti, APRN Registered Nurse Medicare: Medicare Enrolled Practice Location: 131 Bridge St, Naugatuck, CT 06770 Phone: 203-729-0755    Fax: 203-729-0797

Orquidea Rivera, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 40 Brittany Ln, Naugatuck, CT 06770 Phone: 475-351-5200

Mrs. Binbin Yi, Registered Nurse Medicare: Accepting Medicare Assignments Practice Location: 58 Maple St Ste 300, Naugatuck, CT 06770 Phone: 203-709-6646    Fax: 203-709-5288

Paulette Atse, PMHNP -BC Registered Nurse Medicare: Medicare Enrolled Practice Location: 210 Park Ave, Naugatuck, CT 06770 Phone: 203-993-1702

Ms. Alexandra Emily Moss, RN, APRN, NP, B.C. Registered Nurse - Psych/Mental Health Medicare: Medicare Enrolled Practice Location: 576 Rubber Ave, Naugatuck, CT 06770 Phone: 203-500-3208    Fax: 475-227-2085

News Archive

Researchers have identified the cellular receptor for the JC virus

Researchers funded in part by the National Institute of Neurological Disorders and Stroke (NINDS) have identified the cellular receptor for the JC virus, which causes the fatal neurological disease progressive multifocal leukoencephalopathy (PML).

Two families having premature baby visit White House to share their inspiring stories with President Obama

Two families who know all too well the trauma of having a baby born prematurely visited the White House today to share their inspiring stories with President Obama. The Hall family from Leesburg, Va., and the Hoffman family from Weston, Fla., are ambassadors for the March of Dimes, a nonprofit foundation that works to prevent premature birth, birth defects, and infant mortality.

Access Pharmaceuticals initiates Phase I/II dose escalating study for Thiarabine

Access Pharmaceuticals, Inc., today announced it has initiated a Phase I/II dose-escalating study of its proprietary, anti-cancer drug, Thiarabine, a nucleoside analog for patients with hematologic malignancies (cancers of the blood). The primary objective of the study is to determine the maximum tolerated dose (MTD) in two different dosing schedules with various leukemias and lymphomas and recommended Phase II dose. The program is being led by Hagop Kantarjian, M.D., Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.

Hacker Group formalizes dedicated health insurance marketing practice

Hacker Group, one of the largest direct/digital marketing agencies in the West, today announced that it has formalized a dedicated health insurance marketing practice within the agency. Following years of real world experience within the industry, Hacker Group formed HealthHG to address the highly specialized and complex needs of health insurance marketing.

Read more Medical News

› Verified 9 days ago